Guardant Health has launched Guardant360 Tissue, marking a significant advancement in cancer diagnostics as the first molecular profiling test for tumor tissue that incorporates comprehensive multiomics analysis. The test combines DNA, RNA, AI-powered PD-L1 and genome-wide methylation data to provide researchers and cancer care teams with an unprecedented view of individual tumors.
Revolutionary Multiomic Approach
Powered by the Guardant Infinity smart liquid biopsy platform, the Guardant360 Tissue test enables insights beyond what can typically be found using tests that do not incorporate comprehensive analysis of epigenetics. These insights can apply to important classes of therapeutics, such as PARP-inhibitors and immunotherapies, as well as important new classes of therapies in late-stage development.
The test represents the first tissue comprehensive genomic profiling test to offer genome-wide tumor methylation analysis, enabling classification and subtyping of each individual tumor at much higher resolution. This capability potentially enables a new era of precision oncology research and clinical applications.
Addressing Tissue Sample Limitations
A critical advantage of the new test is its efficiency in tissue utilization. The Guardant360 Tissue test requires 92% less tissue surface area for analysis than the industry norm. In a real-world assessment, more than 50% of tumor tissue samples from patients failed to meet the surface area requirement, meaning those patients couldn't qualify for testing.
The new test allows biopharmaceutical researchers and healthcare providers to successfully analyze tissue samples with 40% fewer slides, enabling testing of more patients using less precious tissue. This addresses a significant barrier in cancer diagnostics where tissue availability often limits testing options.
Comprehensive Genomic Coverage
For biopharmaceutical partners, the Guardant360 Tissue test offers differentiated molecular profiling through its extensive genomic and epigenomic capabilities. The test analyzes 742 DNA genes and fusions in 367 RNA genes, with the ability to provide genome-wide analysis of the tumor methylome.
"Guardant360 Tissue establishes a new standard in tissue molecular profiling, enabling insights across additional dimensions to provide biopharma and oncologists with an unprecedented view of each individual tumor," said Helmy Eltoukhy, Guardant Health chairman and co-CEO. "And because it is built on our smart liquid biopsy platform, the test will leverage the countless multiomic applications that are being built around our Guardant360 liquid biopsy ecosystem."
Clinical Implementation and Access
Test results are available in less than two weeks, facilitating rapid clinical decision-making. The Guardant360 Tissue test is covered by Medicare for eligible patients, ensuring broader access to this advanced diagnostic technology.
Eltoukhy emphasized that the synergy between the tissue test and the company's liquid biopsy ecosystem "will provide a new level of clinical actionability and improved patient outcomes across our entire product portfolio."
The launch represents a significant step forward in precision oncology, combining advanced molecular profiling capabilities with practical improvements in tissue utilization efficiency to expand testing access for cancer patients.
